Custom service

Cyclic Peptide Drug Development

Take a cyclic peptide lead through developability assessment

Turnaround: 8–14 weeksTypical scale: 1 – 200 mg cyclic peptideChemistry options: developability profiling (solubility, stability, aggregation); formulation screening; analytical method package

Teams come to this service when they need to take a cyclic peptide lead through developability assessment. We typically start from developability profiling (solubility, stability, aggregation), add formulation screening where the application demands it, and close the loop with analytical method package so the final developability report with recommended form behaves consistently across lots.

Design reviews are part of the schedule, not an extra. Sequence, spacer architecture and analytical strategy are signed off before the first synthesis run, which is why the 8–14 weeks timeline holds in practice.

Pre-IND cyclic lead assessment

Cyclic peptide manufacturing route scouting

IND-enabling toxicology and GLP studies

Cycles whose ring size is known to be geometrically uncloseable

Cyclic products are released against connectivity, not mass alone. MS/MS fragmentation confirms the ring closure, and where multiple topologies are possible the target isomer is isolated and its ratio reported. Protease-stability data are available as an add-on.

Service Highlights

  • Developability profiling (solubility, stability, aggregation) as the default route, with formulation screening held as a proven fallback
  • Analytical method package worked into the design where the application requires it
  • Cyclization strategy (head-to-tail, disulfide, lactam, thioether) chosen from a feasibility screen, not fixed by habit
  • Analytical confirmation of every intermediate before the final release
  • Cyclic/linear and topological isomers separated and reported, with the target isomer identified by MS/MS
  • Developability report with recommended form delivered with a complete conjugation or synthesis certificate

How the work runs

  1. Precursor design

    Linear precursor, cyclization sites and protecting strategy are designed around the Cyclic Peptide Drug Development ring size.

  2. Linear assembly

    The precursor chain is assembled with Fmoc chemistry and developability profiling (solubility, stability, aggregation) where relevant.

  3. Cyclization

    Ring closure is executed by formulation screening under screened dilution and activation conditions.

  4. Isomer separation

    RP-HPLC resolves cyclic/linear and topological isomers; the target isomer is collected.

  5. Characterization

    Connectivity, purity and identity are confirmed by MS/MS and HPLC against the specification.

  6. Release

    Developability report with recommended form is documented and released after QC sign-off.

Specifications & timeline

Turnaround
8–14 weeks
Typical scale
1 – 200 mg cyclic peptide
Chemistry options
developability profiling (solubility, stability, aggregation); formulation screening; analytical method package
Deliverable
Developability report with recommended form
QC package
HPLC purity, MS/MS connectivity proof, isomer ratio, DMSO solubility
Shipping
Ambient with desiccant; blue ice for sensitive motifs

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.